Browsing: Homepage Slider
In this interview we speak to Deepali Kumar about vaccination in the immunocompromised population, including guideline updates, understanding immunology and the future of this field.
Moderna has announced that the first participants have been dosed in a Phase I study of their mRNA candidate vaccine against SARS-CoV-2, the virus that causes COVID-19.
The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
The media are uniquely placed to impact what the public think and feel. During outbreaks what challenges are facing journalists? Editor, Martha Powell, asks how we can ensure we’re undertaking reporting responsibly?
Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.